ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,303.27
      0.12%
      US Tech 100
      18,062.00
      -0.10%
      Dow Jones
      40,003.59
      0.34%
      Brent Oil
      83.655
      -0.13%
      Bitcoin
      66,284.42
      -0.98%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Eloxx Pharmaceuticals Inc (ELOX)

      7. Eloxx Pharmaceuticals Inc (ELOX) News

      ELOX

      Eloxx Pharmaceuticals (ELOX)

      Eloxx Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ELOX
      DateTimeSourceHeadlineSymbolCompany
      04/16/20247:30AMGlobeNewswire Inc.Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program UpdatesNASDAQ:ELOXEloxx Pharmaceuticals Inc
      04/01/20244:02PMEdgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405NASDAQ:ELOXEloxx Pharmaceuticals Inc
      03/29/20244:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      03/21/20242:20PMEdgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
      03/14/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      03/13/202411:42AMGlobeNewswire Inc.Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseasesNASDAQ:ELOXEloxx Pharmaceuticals Inc
      01/26/20244:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
      01/26/20244:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
      01/26/20244:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
      01/26/20244:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
      01/24/20249:44PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELOXEloxx Pharmaceuticals Inc
      01/24/20245:11PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ELOXEloxx Pharmaceuticals Inc
      01/09/20245:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      12/28/20234:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      11/13/20234:15PMGlobeNewswire Inc.Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:ELOXEloxx Pharmaceuticals Inc
      10/16/20235:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      10/09/20238:00AMGlobeNewswire Inc.Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaNASDAQ:ELOXEloxx Pharmaceuticals Inc
      09/20/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      09/20/20231:26PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ELOXEloxx Pharmaceuticals Inc
      09/19/20238:00AMGlobeNewswire Inc.Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ELOXEloxx Pharmaceuticals Inc
      09/18/20238:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      09/18/20237:00AMGlobeNewswire Inc.Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeNASDAQ:ELOXEloxx Pharmaceuticals Inc
      09/15/20235:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      09/07/202310:14AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      09/07/20239:00AMGlobeNewswire Inc.Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013NASDAQ:ELOXEloxx Pharmaceuticals Inc
      08/29/20234:32PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      08/21/20234:50PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      08/14/202311:56AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
      08/14/20238:30AMGlobeNewswire Inc.Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:ELOXEloxx Pharmaceuticals Inc
      08/14/20238:00AMGlobeNewswire Inc.Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeNASDAQ:ELOXEloxx Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:ELOX